Pregabalin
Brand names: Lyrica Cr, Pregabalin Er, Lyrica, Pregabalin
Part of: Gabapentin & pregabalin
At a glance
- Medicare prescriptions, 2024
- 6,738,395
- Medicare drug cost
- $194.0M
- Average cost per prescription
- $28.80
- Clinicians who prescribed it
- 144,443
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 23.1%
- Nurse Practitioners 21.0%
- Internal Medicine 14.9%
- Pain Medicine 11.1%
- Physician Assistants 9.1%
- Neurology 6.7%
- Physical Medicine & Rehabilitation (PM&R) 3.1%
- Rheumatology 2.5%
- Anesthesiology 1.3%
- General Practice 0.9%
- Podiatrists 0.8%
- Geriatric Medicine 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 45% from 2019 to 2024.
Biggest change by state since 2019
- Utah +100%
- Minnesota +86%
- Oregon +84%
- Washington +80%
- Nevada +75%
- Mississippi (smallest change) +13%
- New Jersey (smallest change) +17%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | white capsule, 18 mm | A011 PREG150 |
Proficient Rx LP
| Strength | Looks like | Imprint |
|---|---|---|
| 75 mg | white capsule, 14 mm | SK F PG75 |
| 150 mg | white capsule, 18 mm | SK F PG150 |
Unichem Pharmaceuticals (USA), Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | orange capsule, 14 mm | U 439 |
| 50 mg | orange capsule, 16 mm | U 440 |
| 75 mg | white capsule, 14 mm | U 441 |
| 100 mg | blue capsule, 14 mm | U 442 |
| 150 mg | blue capsule, 18 mm | U 443 |
| 200 mg | blue capsule, 19 mm | U 444 |
| 225 mg | blue capsule, 19 mm | U 445 |
| 300 mg | orange capsule, 21 mm | U 446 |
Viatris Specialty LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 82.5 mg | blue oval tablet, 16 mm | VLE PGN 82 5 |
| 165 mg | brown oval tablet, 18 mm | VLE PGN 165 |
| 330 mg | pink oval tablet, 19 mm | VLE PGN 330 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $1,733 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Mylan Inc. $1,733
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- May 2024 · Rising Pharma Holding, Inc. · Class III
Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg. - Oct 2021 · Sun Pharmaceutical Industries Inc · Class II
Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient. - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.